27th Feb 2024 A plain language summary of the SPRINT study: selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas
27th Feb 2024 A plain language summary looking at nivolumab that is given after stage 2B/2C melanoma is removed by surgery
23rd Feb 2024 A plain language summary looking at the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
25th Jan 2024 The TROPiCS-02 study: a plain language summary on the effectiveness of sacituzumab govitecan in treating HR-positive/HER2-negative breast cancer
25th Jan 2024 The PRIMA study: a plain language summary on the efficacy and safety of individualized niraparib dosing based on body weight and platelet count
22nd Jan 2024 Zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment- a plain language summary
22nd Jan 2024 The TITAN study: a plain language summary looking at how PSA decline with apalutamide therapy is associated with longer survival and improved outcomes in people with metastatic prostate cancer
22nd Jan 2024 Biosimilars and how they can be used to treat people with cancer- a plain language review
22nd Jan 2024 A plain language summary looking at the long-term benefit of sotorasib in patients with KRAS G12C–mutated non–small-cell lung cancer
22nd Jan 2024 The DESTINY-Breast03 study: a plain language summary comparing trastuzumab deruxtecan with trastuzumab emtansine for breast cancer
18th Jan 2024 Plain language summary: looking at the enfortumab vedotin plus pembrolizumab treatment combination for untreated locally advanced or metastatic urothelial cancer
18th Jan 2024 The MOUNTAINEER study: a plain language summary looking at how effective and safe tucatinib plus trastuzumab is for treating people with metastatic colorectal cancer
14th Nov 2023 A plain language summary of the ARROW study: pralsetinib in patients with RET fusion–positive non-small cell lung cancer
3rd Nov 2023 A plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with a long term follow-up
3rd Nov 2023 A plain language summary of the DESTINY-Gastric01 study: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
2nd Nov 2023 A plain language summary of the PALOMA-2 and PALOMA-3 studies: the effects of adding palbociclib to endocrine therapy to treat advanced breast cancer
6th Oct 2023 A plain language summary of the monarcHER study: abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer
6th Oct 2023 The TOPAZ-1 study: a plain language summary describing durvalumab and chemotherapy for advanced biliary tract cancer
22nd Sep 2023 A plain language summary of the HIMALAYA study which looked at tremelimumab and durvalumab for unresectable hepatocellular carcinoma
13th Sep 2023 The effect of vibegron on the blood pressure and heart rate in people with overactive bladder: a plain language summary
12th Sep 2023 A plain language summary describing the effect of rapidly rising prostate-specific antigen (PSA) levels on how long men with a type of advanced prostate cancer live and their healthcare costs
11th Sep 2023 A plain language summary of the INTRIGUE study comparing ripretinib with sunitinib in people with advanced gastrointestinal stromal tumour after treatment with imatinib
17th Aug 2023 Plain Language Summary: looking at patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab in the CHRYSALIS study
10th Aug 2023 A plain language summary looking at whether declines in prostate-specific antigen level indicates how long patients with advanced prostate cancer will live when treated with enzalutamide
9th Aug 2023 The MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma- a plain language summary
1st Aug 2023 Plain Language Summary: looking at how long side effects last after stopping axitinib treatment in people with advanced renal cell carcinoma
13th Jul 2023 Plain Language Summary: xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck
11th Jul 2023 Plain Language Summary: the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
29th Jun 2023 Plain Language Summary: the GARNET study, dostarlimab for the treatment of endometrial cancer
21st Jun 2023 Plain Language Summary: updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer
20th Jun 2023 Encorafenib and binimetinib for people with BRAF V600-mutant melanoma, 5-year update of the COLUMBUS study- Plain Language Summary
23rd May 2023 Plain Language Summary: the MAIA study, daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
23rd May 2023 Plain Language Summary: tepotinib, a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping
23rd May 2023 Plain Language Summary: treatment considerations for patients with advanced squamous cell carcinoma of the lung
16th May 2023 Plain Language Summary: the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies
15th May 2023 Plain Language Summary: the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
13th Apr 2023 A Plain Language Summary and a patient perspective of the 2020 lung cancer screening recommendations given by the US Preventive Services Task Force
13th Apr 2023 A Plain Language Summary and a patient perspective of the recommendations made by the European Society for Medical Oncology on treating EGFR-positive non-small-cell lung cancer
13th Apr 2023 A Plain Language Summary with patient perspective’s of the revised STARS study: Long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung cancer (NSCLC)
13th Apr 2023 A Plain Language Summary and a patient perspective of the American Society for Clinical Oncology guideline: management of stage 3 non-small-cell lung cancer
12th Apr 2023 Plain Language Summary: managing metastatic prostate cancer by integrating radium-223 therapy
12th Apr 2023 Plain Language Summary: the CheckMate 274 study, treatment of muscle-invasive urothelial cancer with nivolumab
12th Apr 2023 Plain Language Summary: the CheckMate 816 study, nivolumab plus chemotherapy given before surgery for NSCLC
12th Apr 2023 Plain Language Summary: a real-world database analysis on prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor
12th Apr 2023 Plain Language Summary : iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström’s macroglobulinemia
12th Apr 2023 Plain Language Summary: Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations
11th Apr 2023 Plain Language Summary: the development and validation of risk calculators for people with “thin” melanomas on their skin to predict the likelihood that their cancer will return